Gamida Cell receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Investing.com - Gamida Cell (NASDAQ: GMDA) reported first quarter EPS of $-0.270, $0.01 better than the analyst estimate of $-0.280. Revenue for the quarter came in at $0.00...
Gamida Cell Ltd. (Nasdaq: NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of...
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:Delek US Holdings, Inc. (NYSE:DK) is engaged in the integrated downstream energy business. The Zacks...
Gamida Cell Ltd. (NASDAQ:GMDA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors...
Gamida Cell Ltd. (NASDAQ:GMDA) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GMDA recently saw a Hammer Chart Pattern which...
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
| Average | 6.800 (+211.927% Upside) |
| High | 11.000 |
| Low | 5.000 |
| Price | 2.180 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Sell | Buy | Neutral |
| Technical Indicators | Neutral | Strong Sell | Strong Sell | Buy | Sell |
| Summary | Neutral | Strong Sell | Strong Sell | Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 122.94 | 129.55 | 122.63 | -4.97 | -3.89% | 32.88M | NASDAQ | |||
| 23.12 | 25.38 | 22.34 | -1.37 | -5.59% | 1.30M | NASDAQ | |||
| 0.40 | 0.47 | 0.38 | -0.03 | -6.10% | 927.90K | OTC Markets | |||
| 211.21 | 211.85 | 208.00 | +4.05 | +1.96% | 3.27M | NYSE | |||
| 11.88 | 12.10 | 11.68 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 4.71 | 5.12 | 4.13 | +1.03 | +27.99% | 24.34M | NASDAQ | |||
| 1.93 | 1.94 | 1.70 | +0.38 | +24.52% | 797.96K | NASDAQ | |||
| 7.76 | 7.97 | 7.58 | -0.12 | -1.52% | 46.91M | NYSE | |||
| 3.85 | 3.85 | 3.85 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 1.06 | 1.06 | 1.06 | -0.340 | -24.29% | 102.00 | OTC Markets | |||
| 92.52 | 93.08 | 91.86 | +0.36 | +0.39% | 11.01M | NYSE | |||
| 57.22 | 60.48 | 57.12 | -1.93 | -3.26% | 3.83M | NASDAQ | |||
| 10.30 | 10.45 | 10.06 | -0.02 | -0.19% | 7.96M | NYSE | |||
| 31.31 | 31.36 | 30.80 | +0.23 | +0.74% | 10.56M | NASDAQ | |||
| 36.95 | 37.53 | 36.61 | -0.80 | -2.12% | 10.82M | NASDAQ |